Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Lymphoid 1Breast 1

Conditions

Neoplasms 1Lymphoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 3copanlisib 2aflibercept 2X-Rays 2Specimen Handling 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1selinexor 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1epacadostat 1enzalutamide 1entinostat 1defactinib 1dabrafenib 1ciforadenant 1capivasertib 1binimetinib 1atezolizumab 1adavosertib 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Miransertib × Lymphoid × Clear all
NCT01473095 2017-10-23

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
120 enrolled
GynecologicLymphoid

Lymphoma, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡